Novartis Takes Aim: Galvus Promotions To Target Other Classes, Not Januvia
Executive Summary
Novartis' strategy for launching its dipeptidyl peptidase IV inhibitor Galvus will be to position the antidiabetic as an option against other existing therapeutic classes, not head-to-head against Merck's DPP-IV Januvia
You may also be interested in...
Novartis Touts Galvus Efficacy Vs. Januvia After Metformin Comparison Fails
Novartis is highlighting the superior efficacy of its dipeptidyl peptidase-4 inhibitor Galvus relative to Merck's recently launched DPP-4 agent Januvia.
Novartis Touts Galvus Efficacy Vs. Januvia After Metformin Comparison Fails
Novartis is highlighting the superior efficacy of its dipeptidyl peptidase-4 inhibitor Galvus relative to Merck's recently launched DPP-4 agent Januvia.
Januvia Clears FDA; Sitagliptin Has “Neutral Effects” On Weight, Agency Says
Merck's dipeptidyl peptidase IV inhibitor Januvia has no significant effect on weight, FDA said after approving sitagliptin for type 2 diabetes Oct. 16